Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling. |
|
Device | ELECSYS ANTI-HCV II IMMUNOASSAY, ELECSYS PRECICONTROL ANTI-HCV |
Generic Name | Assay, enzyme linked immunosorbent, hepatitis c virus |
Applicant | ROCHE DIAGNOSTICS OPERATIONS INC 9115 HAGUE ROAD P.O. BOX 50416 INDIANAPOLIS, IN 46250-0416 |
PMA Number | P140021 |
Date Received | 10/01/2014 |
Decision Date | 06/11/2015 |
Reclassified Date
|
12/22/2021 |
Product Code |
MZO |
Docket Number | 15M-2217 |
Notice Date | 07/10/2015 |
Advisory Committee |
Microbiology |
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement APPROVAL FOR THE ELECSYS ANTI-HCV II IMMUNOASSAY AND ELECSYS PRECICONTROL ANTI-HCV. THIS DEVICE IS INDICATED FOR: ELECSYS ANTI-HCV II IMMUNOASSAYIMMUNOASSAY FOR THE IN VITRO QUALITATIVE DETECTION OF ANTIBODIES TO HEPATITIS C VIRUS (HCV) IN HUMAN ADULT AND PEDIATRIC (AGES 18 MONTHS THROUGH 21 YEARS) SERUM AND PLASMA (POTASSIUM EDTA, LITHIUM HEPARIN, SODIUM HEPARIN, AND SODIUM CITRATE). ASSAY RESULTS, IN CONJUNCTION WITH OTHER LABORATORY RESULTS AND CLINICAL INFORMATION, MAY BE USED TO AID IN THE PRESUMPTIVE DIAGNOSIS OF HCV INFECTION IN PERSONS WITH SIGNS AND SYMPTOMS OF HEPATITIS AND IN PERSONS AT RISK FOR HEPATITIS C INFECTION. THE TEST DOES NOT DETERMINE THE STATE OF INFECTION OR ASSOCIATED DISEASE.THE ELECTROLUMINESCENCE IMMUNOASSAY ECLIA IS INTENDED FOR USE ON THE ROCHE COBAS E 601 IMMUNOASSAY ANALYZER.ELECSYS PRECICONTROL ANTI-HCV ELECSYS PRECICONTROL ANTI-HCV IS USED FOR QUALITY CONTROL OF THE ELECSYS ANTI-HCV IMMUNOASSAY ON THE COBAS E 601 AND COBAS E 602 IMMUNOASSAY ANALYZERS AND THE ELECSYS ANTI-HCV II IMMUNOASSAY ON THE COBAS E 601 IMMUNOASSAY ANALYZER. |
Approval Order | Approval Order |
Summary | Summary of Safety and Effectiveness |
Labeling | Labeling
|
Supplements: |
S001 S002 S003 S004 S005 S006 S007 S008 S009 S010 S011 S012 S013 S014 S015 S016 |
|
|